VBI Vaccines (NASDAQ:VBIV) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Saturday. The brokerage presently has a $5.25 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 15.64% from the company’s current price.

According to Zacks, “VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus vaccine. Its second platform is a thermostable technology that enables the development of vaccines and biologics. VBI Vaccines Inc., formerly known as SciVac Therapeutics, Inc., is headquartered in Cambridge, MA. “

A number of other brokerages have also recently commented on VBIV. BidaskClub cut VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. BMO Capital Markets initiated coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Canaccord Genuity initiated coverage on VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price target for the company. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. VBI Vaccines presently has a consensus rating of “Hold” and an average target price of $8.75.

Shares of VBI Vaccines (NASDAQ VBIV) opened at $4.54 on Friday. The firm has a market capitalization of $289.67, a price-to-earnings ratio of -6.22 and a beta of 1.73. VBI Vaccines has a twelve month low of $3.03 and a twelve month high of $6.60. The company has a quick ratio of 0.97, a current ratio of 1.03 and a debt-to-equity ratio of 0.19.

In related news, major shareholder Life Sciences Maste Perceptive bought 3,100,000 shares of the stock in a transaction that occurred on Thursday, October 26th. The stock was acquired at an average cost of $3.05 per share, with a total value of $9,455,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeff Baxter bought 10,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The shares were bought at an average cost of $3.89 per share, with a total value of $38,900.00. Following the completion of the transaction, the chief executive officer now owns 140,646 shares in the company, valued at $547,112.94. The disclosure for this purchase can be found here. Insiders bought a total of 4,080,738 shares of company stock valued at $12,480,151 over the last quarter. 54.50% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in VBIV. California State Teachers Retirement System bought a new position in VBI Vaccines during the 2nd quarter worth $167,000. Schwab Charles Investment Management Inc. bought a new position in VBI Vaccines during the 2nd quarter worth $187,000. Bank of New York Mellon Corp bought a new position in shares of VBI Vaccines in the 2nd quarter worth about $193,000. Teachers Advisors LLC bought a new position in shares of VBI Vaccines in the 2nd quarter worth about $195,000. Finally, TIAA CREF Investment Management LLC bought a new position in shares of VBI Vaccines in the 2nd quarter worth about $262,000. 20.93% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://theolympiareport.com/2017/12/25/vbi-vaccines-vbiv-stock-rating-upgraded-by-zacks-investment-research.html.

About VBI Vaccines

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with Analyst Ratings Network's FREE daily email newsletter.